GENMAB A/S (GMAB)

What GENMAB A/S does

is subject to numerous risks and uncertainties. You should carefully consider these risks and uncertainties when investing in our ordinary shares or American depositary shares (“ADSs”). The principal risks and uncertainties affecting our business include the following: •The substantial majority of our revenue comes from royalties on sales of DARZALEX, and our patents underlying these royalties will start to expire in the late 2020s. •Our launch of a new product or of an existing product in a new indication or territory is subject to a number of risks and uncertainties and may not be successful. •Our business and operations have experienced rapid growth that needs to be carefully managed.

Verify the company description in the original SEC filing

Open the company story

The live GraceFinance page shows source-backed financial changes, management context, guidance, confirmed events, risks, and connected history only when the applicable evidence and relationships have been established. Missing research stays visible instead of being inferred.